Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-PHP vs TCbHP in HER2-positive early breast cancer
NCT04547907Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in HER2-positive breast cancer, sponsored by Henan Cancer Hospital. Started Sep 2020; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04547907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547907.